At the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California, David Andorsky, MD, Rocky Mountain Cancer Centers, discussed updated findings from the Symphony-1 trial after a 22.5-month follow-up, which demonstrated the continuous efficacy and safety of the tazemetostat plus lenalidomide and rituximab treatment combination among patients with relapsed/refractory (R/R) follicular lymphoma (FL).

Transcript:

Hi, good afternoon. My name is Dr. David Andorsky. I'm speaking to you from ASH 2023. I'm a medical oncologist [and] hematologist at the Rocky Mountain Cancer Center in Boulder, Colorado, and I'm a member of the Sarah Cannon Research Institute, Lymphoma Executive Research Committee. I'm here to talk a bit about a presentation that I'm a co-investigator on, looking at the use of Revlimid (lenalidomide) and rituximab therapy with or without tazemeteostat in the treatment of relapsed and refractory follicular lymphoma. 

Revlimid and rituximab, often called R2, is a very commonly used second or third line regimen for the treatment of follicular lymphoma. It's [an] exclusively targeted therapy, no chemotherapy, and it's very effective and safe in treating patients with that disease. Tazemetostat is a newer oral medication that inhibits the protein called EZH2, which is felt to be an important epigenetic regulator of follicular lymphoma cell growth. Tazemetostat is approved as a single agent for the treatment of follicular lymphoma and the third line to be on. 

What our study is looking at is combining that R2 backbone with tazemetostat. The study has 2 parts. The first was a phase 1 safety run-in where all patients got R2 with increasing doses of tazemetostat. The study is now in the second phase, which is a phase 3 study looking at randomizing patients to R2 with or without tazemetostat. The report that we made and are presenting at ASH this year is looking at the first portion of the study where all patients received R2 with tazemetostat at increasing doses. 

[A total of] 44 patients were available for analysis, and we saw what we thought were very promising response rates, so about 90% overall response rate, which is seemingly higher than you would expect with either R2 or tazemetostat alone. 

The toxicities that we saw were primarily hematologic and pretty much in line with what you'd expect to see with the R2 regimen. We think this regimen has a lot of promise in terms of improving the overall response rate and progression-free survival, and hopefully overall survival, without adding much in the way of side effects. 

We're looking forward to enrolling more patients in the phase 3 portion so we can accrue that study and then have more definitive data that this is really a promising treatment. Thank you for your attention.

Source: 

Salles G, Park SI, Phillips TJ, et al. Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up. Presented at the ASH 65th Annual Meeting & Exposition; December 9-12 2023; San Diego, California. Abstract 3035